사이클로포스파마이드 치료 후 심한 백혈구감소증을 보인 Cytochrome P450 2A6*1B 변이형을 가진 환자 1예Severe Leukopenia after Intravenous Cyclophosphamide Pulse Therapyin a Patient Having Cytochrome P450 2A6*1B
- Other Titles
- Severe Leukopenia after Intravenous Cyclophosphamide Pulse Therapyin a Patient Having Cytochrome P450 2A6*1B
- Authors
- 성상석; 윤재희; 김은영; 신재국; 전재범; 배상철
- Issue Date
- Jun-2007
- Publisher
- 대한류마티스학회
- Keywords
- Cyclophosphamide; Leukopenia; Cytochrome P450; Cyclophosphamide; Leukopenia; Cytochrome P450
- Citation
- 대한류마티스학회지, v.14, no.2, pp.144 - 148
- Indexed
- KCI
- Journal Title
- 대한류마티스학회지
- Volume
- 14
- Number
- 2
- Start Page
- 144
- End Page
- 148
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/179951
- ISSN
- 2093-940X
- Abstract
- Cyclophosphamide, a prodrug requiring metabolic activation by cytochrome P450 (CYP) enzymes, is used widely for proliferative lupus nephritis and various CYP isoenzymes have been demonstrated to be involved in the bioactivation of cyclophosphamide in humans, including CYP2A6, 2B6, 2C19, 2C9, 3A4, and 3A5. The response or adverse event after intravenous cyclophosphamide pulse therapy in lupus nephritis patient seems to be different for each individual and genetic polymorphism of CYP may explain the difference. Generally, wild types of CYP seem to be more active in the activation of cyclophosphamide than variant types of CYP. Here, we report a case of lupus nephritis with a genotype of CYP2A6*1B who suffered from severe leukopenia after intravenous cyclophosphamide pulse therapy.
- Files in This Item
-
Go to Link
- Appears in
Collections - 서울 의과대학 > 서울 내과학교실 > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.